Larada Sciences v. Pediatric Hair Solutions

CourtDistrict Court, D. Utah
DecidedJune 16, 2025
Docket2:18-cv-00551
StatusUnknown

This text of Larada Sciences v. Pediatric Hair Solutions (Larada Sciences v. Pediatric Hair Solutions) is published on Counsel Stack Legal Research, covering District Court, D. Utah primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Larada Sciences v. Pediatric Hair Solutions, (D. Utah 2025).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF UTAH

LARADA SCIENCES, INC., a Delaware MEMORANDUM DECISION AND corporation, ORDER

Plaintiff, Case No. 2:18-cv-00551-RJS-JCB

v. Chief Judge Robert J. Shelby

PEDIATRIC HAIR SOLUTIONS Magistrate Judge Jared C. Bennett CORPORATION, a North Carolina corporation, et al.,

Defendants.

Before the Court are four Motions: (1) Defendant John Fassler (Dr. Fassler)’s Renewed Partial Motion for Judgment as a Matter of Law;1 (2) Defendants’ Motion for a New Trial and/or Remittitur;2 (3) Defendants’ Emergency Motion to Stay Proceedings to Enforcement of Judgment;3 and (4) Plaintiff Larada Sciences, Inc. (Larada)’s Motion for Attorneys’ Fees4 and Bill of Costs.5 For the reasons explained below, the court DENIES Dr. Fassler’s Motion for Judgment as a Matter of Law, DENIES Defendants’ Motion for a New Trial and/or Remittitur, DENIES Defendants’ Motion to Stay, GRANTS IN PART Larada’s Motion for Attorneys’ Fees, and GRANTS Larada’s Bill of Costs.

1 Dkt. 359, Defendant Dr. John Fassler’s Renewed Partial Motion for Judgment as a Matter of Law (JMOL Motion). 2 Dkt. 360, Defendants’ Motion for a New Trial and/or Remittitur (New Trial Motion). 3 Dkt. 369, Defendants’ Emergency Motion to Stay Proceedings to Enforcement of Judgment (Motion to Stay). 4 Dkt. 348, Plaintiff’s Motion for Attorneys’ Fees (Attorneys’ Fees Motion). 5 Dkt. 346, Bill of Costs. BACKGROUND6 This action concerns the conduct of Defendants Pediatric Hair Solutions Corporation (PHS), Dr. John Fassler, and Sheila Fassler (Defendants), which resulted in a unanimous jury verdict against them for trade secrets misappropriation, related breaches of contract, and breach of the duty of good faith and fair dealing by PHS.7

In 2006, several individuals formed Larada to build a new device to treat head lice.8 Larada engaged in research and development for several years, and it brought its first device, the LouseBuster, to market in 2010.9 The LouseBuster later became known as the AirAllé.10 The AirAllé works by directing heated air onto patients’ scalps, and it is highly effective at eliminating lice.11 It is the only FDA-cleared device of its kind on the market.12 Larada has developed newer versions of the AirAllé over the last decade.13 To operate, the AirAllé employs Larada’s four trade secrets: (1) the specific air output parameter values for temperature and volumetric flow rate; (2) the method by which Larada achieves efficacy with a single de-lousing treatment alone, by only pairing Larada’s multi-nozzle

tip with the AirAllé unit and vice-versa; (3) the method, process and design Larada developed and applied for effectively fast thermal control response in a high-discharge heated air device;

6 Relying on the evidence Larada introduced at trial, the court recites the facts in the light most favorable to Larada because it is considering Defendants’ Motions under Federal Rules of Civil Procedure 50 and 59. See Lompe v. Sunridge Partners, LLC, 818 F.3d 1041, 1061–62 (10th Cir. 2016). 7 Dkt. 332, Jury Verdict Form. 8 Dkt. 374, Trial Testimony of Claire Roberts at 5145:14–5146:13. 9 Id. at 5149:4–15. 10 Id. at 5149:10–11. 11 Id. at 5166:10–19, 5206:5–5207:7. 12 Id. at 5177:11–21. 13 Id. at 5162:14–5166:9. and (4) Larada’s specific selection and method of utilization of the blower-related components as applying them for the purpose of precise volumetric delivery and flow control.14 Larada licenses the use of the AirAllé to independent clinics and works with over one hundred such clinics across the country.15 One of these clinics was PHS, a company based in North Carolina.16 Ms. Fassler, a nurse, is the sole owner of PHS, and Dr. John Fassler is its

National Medical Director.17 The Fasslers are married.18 Beginning in 2010, Defendants entered into a series of agreements with Larada governing their use of Larada’s devices (the Agreements).19 The Agreements include License Agreements, a Lease Agreement, and a Consulting Agreement.20 The Agreements contain restrictions on Defendants’ use of Larada’s confidential or proprietary information,21 including prohibitions on disassembling, reverse-engineering, or otherwise copying Larada’s devices.22 Over the next several years, Defendants participated in a systematic and deliberate effort to exploit Larada’s trade secrets by building, marketing, and benefiting from their own, competing devices. More specifically, Dr. Fassler first reached out to a product designer, Kevin

14 See Post Evidence Instruction No. 33; Dkt. 268-2, Defendants’ Ex. 1097, Expert Report of Jon Beck at 8–11. 15 Trial Testimony of Claire Roberts at 5166:10–5167:15, 5170:19–20. 16 Id. at 5171:3–14; Dkt. 386, Trial Testimony of Sheila Fassler (Day 1) at 5941:10–17. 17 Trial Testimony of Sheila Fassler (Day 1) at 5935:16–22, 5947:2–10. 18 Id. at 5936:4–17. 19 See Defendants’ Exs. 1003, 1212–18, License Agreements (various agreements between Larada and PHS signed by Ms. Fassler); Plaintiff’s Ex. 81, Lease Agreement (binding PHS and Ms. Fassler personally); Plaintiff’s Ex. 118, Consulting Agreement (signed by Dr. Fassler). See also Trial Testimony of Claire Roberts at 5171:6–5179:20; Trial Testimony of Sheila Fassler (Day 1) at 5938:10–5940:9. 20 See Agreements. 21 See id.; see also Trial Testimony of Claire Roberts at 5172:12–5179:20; Trial Testimony of Sheila Fassler (Day 1) at 5938:23–5940:9. 22 Trial Testimony of Sheila Fassler (Day 1) at 5942:23–5943:20; see also Defendants’ Exs. 1003, 1212–18, License Agreements; Plaintiff’s Ex. 81, Lease Agreement. Dahlquist, and his firm, Caliber Design, in late 2014.23 Dr. Fassler inquired about assistance with “manufacturing” a device “similar” to the AirAllé.24 After engaging Mr. Dahlquist’s services, Defendants provided him with “at least five” Larada devices, which he then used to design and manufacture competing devices for Defendants.25 Defendants later involved another firm, Enventys Partners, to continue product development.26 Defendants named their resulting

device the FloSonix.27 The AirAllé and Larada’s trade secrets within it were crucial to Defendants’ development of the FloSonix.28 For several months in early 2017, one or more Defendants oversaw the “Clinical Results Comparison Study,” which tested the efficacy of the FloSonix against the AirAllé.29 The Study report indicates it took place at PHS, and it lists Dr. Fassler and Ms. Fassler on its front page as “Medical Director” and “CEO,” respectively.30 In May of that same year, Ms. Fassler formed FloSonix Ventures, LLC (FSV).31 While Ms. Fassler is FSV’s sole owner,32 at some point Dr. Fassler provided FSV with a $100,000 loan.33 Through FSV, Defendants began encouraging clinic owners who licensed the AirAllé from Larada to use the FloSonix instead.34 Then, after

23 Plaintiff’s Ex. 216, Sept. 26, 2014 Email from John Fassler to Kevin Dahlquist. 24 Id. 25 See Trial Testimony of Sheila Fassler (Day 1) at 5951:12–5962:20; Dkt. 378, Trial Testimony of Sheila Fassler (Day 2) at 5296:23–5297:2. 26 See Dkt. 384, Trial Testimony of Jeremy Losaw at 5747:20–5771:20. 27 Trial Testimony of Sheila Fassler (Day 2) at 5351:12–25. 28 See, e.g., Dkt. 373, Trial Testimony of Jon Beck (Day 1), at 5135:18–5137:22. 29 See Plaintiff’s Ex. 110, Clinical Results Comparison Study. 30 Id. 31 Trial Testimony of Sheila Fassler (Day 2) at 5342:4–16. 32 Trial Testimony of Sheila Fassler (Day 1) at 5935:23–5936:3. 33 Dkt. 376, Trial Testimony of John Fassler at 5244:24–20. 34 Trial Testimony of Claire Roberts at 5193:14–5194:24.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

General Universal Systems, Inc. v. Hal, Inc.
500 F.3d 444 (Fifth Circuit, 2007)
Hensley v. Eckerhart
461 U.S. 424 (Supreme Court, 1983)
Blum v. Stenson
465 U.S. 886 (Supreme Court, 1984)
Crawford Fitting Co. v. J. T. Gibbons, Inc.
482 U.S. 437 (Supreme Court, 1987)
BMW of North America, Inc. v. Gore
517 U.S. 559 (Supreme Court, 1996)
State Farm Mutual Automobile Insurance v. Campbell
538 U.S. 408 (Supreme Court, 2003)
Weese v. Schukman
98 F.3d 542 (Tenth Circuit, 1996)
Greene v. Safeway Stores, Inc.
98 F.3d 554 (Tenth Circuit, 1996)
Case v. Unified School District No. 233
157 F.3d 1243 (Tenth Circuit, 1998)
Anaeme v. Diagnostek, Inc.
164 F.3d 1275 (Tenth Circuit, 1999)
Bancoklahoma Mortgage Corp. v. Capital Title Co.
194 F.3d 1089 (Tenth Circuit, 1999)
United Phosphorus, Ltd. v. Midland Fumigant, Inc.
205 F.3d 1219 (Tenth Circuit, 2000)
Shaw v. AAA Engineering & Drafting, Inc.
213 F.3d 519 (Tenth Circuit, 2000)
Cadena v. Pacesetter Corp.
224 F.3d 1203 (Tenth Circuit, 2000)
Brown v. City And County Of
227 F.3d 1278 (Tenth Circuit, 2000)
Hampton v. Dillard Department Stores, Inc.
247 F.3d 1091 (Tenth Circuit, 2001)
Barber v. T.D. Williamson, Inc.
254 F.3d 1223 (Tenth Circuit, 2001)
Webco Industries, Inc. v. Thermatool Corp.
278 F.3d 1120 (Tenth Circuit, 2002)
Biocore Medical v. Khosrowshahi
80 F. App'x 619 (Tenth Circuit, 2003)

Cite This Page — Counsel Stack

Bluebook (online)
Larada Sciences v. Pediatric Hair Solutions, Counsel Stack Legal Research, https://law.counselstack.com/opinion/larada-sciences-v-pediatric-hair-solutions-utd-2025.